167 related articles for article (PubMed ID: 20228781)
1. HMGA2: a biomarker significantly overexpressed in high-grade ovarian serous carcinoma.
Mahajan A; Liu Z; Gellert L; Zou X; Yang G; Lee P; Yang X; Wei JJ
Mod Pathol; 2010 May; 23(5):673-81. PubMed ID: 20228781
[TBL] [Abstract][Full Text] [Related]
2. [Overexpression of high mobility group A2 and its correlation with microRNA let-7 family in serous ovarian cancers].
Yang J; Zhang Q; Dong JQ; Chang XH; He XJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):749-54. PubMed ID: 23073586
[TBL] [Abstract][Full Text] [Related]
3. Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma.
McMillen BD; Aponte MM; Liu Z; Helenowski IB; Scholtens DM; Buttin BM; Wei JJ
Mod Pathol; 2012 Dec; 25(12):1644-53. PubMed ID: 22790015
[TBL] [Abstract][Full Text] [Related]
4. HMGA2 and high-grade serous ovarian carcinoma.
Wu J; Wei JJ
J Mol Med (Berl); 2013 Oct; 91(10):1155-65. PubMed ID: 23686260
[TBL] [Abstract][Full Text] [Related]
5. HMGA2: a potential biomarker complement to P53 for detection of early-stage high-grade papillary serous carcinoma in fallopian tubes.
Wei JJ; Wu J; Luan C; Yeldandi A; Lee P; Keh P; Liu J
Am J Surg Pathol; 2010 Jan; 34(1):18-26. PubMed ID: 19898227
[TBL] [Abstract][Full Text] [Related]
6. STC2 overexpression mediated by HMGA2 is a biomarker for aggressiveness of high-grade serous ovarian cancer.
Wu J; Lai M; Shao C; Wang J; Wei JJ
Oncol Rep; 2015 Sep; 34(3):1494-502. PubMed ID: 26165228
[TBL] [Abstract][Full Text] [Related]
7. HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes.
Wu J; Liu Z; Shao C; Gong Y; Hernando E; Lee P; Narita M; Muller W; Liu J; Wei JJ
Cancer Res; 2011 Jan; 71(2):349-59. PubMed ID: 21224353
[TBL] [Abstract][Full Text] [Related]
8. miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma.
Kim TH; Song JY; Park H; Jeong JY; Kwon AY; Heo JH; Kang H; Kim G; An HJ
Cancer Lett; 2015 Jan; 356(2 Pt B):937-45. PubMed ID: 25444913
[TBL] [Abstract][Full Text] [Related]
9. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
10. HMGA2, but not HMGA1, is overexpressed in human larynx carcinomas.
Palumbo A; De Martino M; Esposito F; Fraggetta F; Neto PN; Valverde Fernandes P; Santos IC; Dias FL; Nasciutti LE; Meireles Da Costa N; Fusco A; Ribeiro Pinto LF
Histopathology; 2018 Jun; 72(7):1102-1114. PubMed ID: 29266325
[TBL] [Abstract][Full Text] [Related]
11. Shortening of the 3' untranslated region: an important mechanism leading to overexpression of HMGA2 in serous ovarian cancer.
He X; Yang J; Zhang Q; Cui H; Zhang Y
Chin Med J (Engl); 2014; 127(3):494-9. PubMed ID: 24451956
[TBL] [Abstract][Full Text] [Related]
12. High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature.
Hatano Y; Tamada M; Asano N; Hayasaki Y; Tomita H; Morishige KI; Hara A
Diagn Pathol; 2019 Jan; 14(1):4. PubMed ID: 30636633
[TBL] [Abstract][Full Text] [Related]
13. Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers.
Helland Å; Anglesio MS; George J; Cowin PA; Johnstone CN; House CM; Sheppard KE; Etemadmoghadam D; Melnyk N; Rustgi AK; Phillips WA; Johnsen H; Holm R; Kristensen GB; Birrer MJ; ; Pearson RB; Børresen-Dale AL; Huntsman DG; deFazio A; Creighton CJ; Smyth GK; Bowtell DD
PLoS One; 2011 Apr; 6(4):e18064. PubMed ID: 21533284
[TBL] [Abstract][Full Text] [Related]
14. MiR-219-5p inhibits growth and metastasis of ovarian cancer cells by targeting HMGA2.
Xing F; Song Z; He Y
Biol Res; 2018 Nov; 51(1):50. PubMed ID: 30474570
[TBL] [Abstract][Full Text] [Related]
15. HMGA1 and HMGA2 expression and comparative analyses of HMGA2, Lin28 and let-7 miRNAs in oral squamous cell carcinoma.
Sterenczak KA; Eckardt A; Kampmann A; Willenbrock S; Eberle N; Länger F; Kleinschmidt S; Hewicker-Trautwein M; Kreipe H; Nolte I; Murua Escobar H; Gellrich NC
BMC Cancer; 2014 Sep; 14():694. PubMed ID: 25245141
[TBL] [Abstract][Full Text] [Related]
16. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
17. MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma.
Liu Z; Liu J; Segura MF; Shao C; Lee P; Gong Y; Hernando E; Wei JJ
J Pathol; 2012 Oct; 228(2):204-15. PubMed ID: 22322863
[TBL] [Abstract][Full Text] [Related]
18. HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases.
Hetland TE; Holth A; Kærn J; Flørenes VA; Tropé CG; Davidson B
Virchows Arch; 2012 May; 460(5):505-13. PubMed ID: 22476403
[TBL] [Abstract][Full Text] [Related]
19. Frequent overexpression of HMGA2 in human atypical teratoid/rhabdoid tumor and its correlation with let-7a3/let-7b miRNA.
Zhang K; Gao H; Wu X; Wang J; Zhou W; Sun G; Wang J; Wang Y; Mu B; Kim C; Chu P; Ho DM; Ann DK; Wong TT; Yen Y
Clin Cancer Res; 2014 Mar; 20(5):1179-89. PubMed ID: 24423609
[TBL] [Abstract][Full Text] [Related]
20. [Construction of let-7d expression vector and its inhibitory effect on HMGA2 and ras expression in human ovarian cancer cells in vitro].
Ye H; Chen J; Huang X; Guo A; Hao P
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Dec; 32(12):1752-7. PubMed ID: 23268403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
